miR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 8309-8318

  Gao, Ling ^a   Yang, Yijin ^b   Xu, Haiyan ^b   Liu, Ruqian ^c   Li, Dechun ^a   Hong, Han ^d   Qin, Mingde ^e   Wang, Yunliang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c No 3 People's Hospital   (China)

^d SUZHOU MUNICIPAL HOSPITAL   (China)

^e SOOCHOW UNIVERSITY   (China)

Author keywords

miR 335; OCT4; Pancreatic cancer; Stem cell; Tumorigenesis

Indexed keywords

MICRORNA; MIRN335 MICRORNA, HUMAN; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN;

CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; METASTASIS; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PANCREATIC NEOPLASMS;

EID: 84922393597     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2092-9     Document Type: Article

References (37)

1. Keane MG, Bramis K, Pereira SP, Fusai GK. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol. 2014;20(9):2267–78.
2. He J, Page AJ, Weiss M, Wolfgang CL, Herman JM, Pawlik TM. Management of borderline and locally advanced pancreatic cancer: where do we stand? World J Gastroenterol. 2014;20(9):2255–66.
3. Herreros-Villanueva M, Bujanda L, Billadeau DD, Zhang JS. Embryonic stem cell factors and pancreatic cancer. World J Gastroenterol. 2014;20(9):2247–54.
4. Iki K, Pour PM. Expression of Oct4, a stem cell marker, in the hamster pancreatic cancer model. Pancreatology. 2006;6(4):406–13.
5. Wang D, Zhu H, Zhu Y, Liu Y, Shen H, Yin R, et al. Su Z.CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. Acta Histochem. 2013;115(4):349–56.
6. Wang H, Wang S, Hu J, Kong Y, Chen S, Li L, et al. Oct4 is expressed in Nestin-positive cells as a marker for pancreatic endocrine progenitor. Histochem Cell Biol. 2009;131(5):553–63.
7. Wen J, Park JY, Park KH, Chung HW, Bang S, Park SW, et al. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas. 2010;39(5):622–6.
8. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70(24):10433–44.
9. Park KS, Shin SW, Choi JW, Um SH. Specific protein markers for stem cell cross-talk with neighboring cells in the environment. Int J Stem Cells. 2013;6(2):75–86.
10. Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, et al. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets. 2012;16(10):1041–54.
11. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013;342(6159):1234850.
12. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328–37.
13. Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther. 2013;6:1249–59.
14. Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet. 2014;5:54.
15. Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, et al. MicroRNAs in the DNA damage/repair network and cancer. Int J Genomics. 2014;2014:820248.
16. Takahashi RU, Miyazaki H, Ochiya T. The role of microRNAs in the regulation of cancer stem cells. Front Genet. 2014;4:295.
17. Hauptman N, Glavac D. MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol. 2013;47(4):311–8.
18. Cheng Q, Yi B, Wang A, Jiang X. Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther. 2013;6:1675–84.
19. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25(3):226–31.
20. Lynch J, Meehan MH, Crean J, Copeland J, Stallings RL, Bray IM. Metastasis suppressor microRNA-335 targets the formin family of actin nucleators. PLoS ONE. 2013;8(11):e78428.
21. Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N. Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers. 2013;35(5):369–87.
22. Wang Y, Zhao W, Fu Q. miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem. 2013;384(1–2):105–11.
23. Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Yang Y, et al. miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer Res. 2014;12(1):101–10.
24. Wang H, Li M, Zhang R, Wang Y, Zang W, Ma Y, et al. Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299. Tumour Biol. 2013;34(5):3101–9.
25. Cao J, Cai J, Huang D, Han Q, Yang Q, Li T, et al. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep. 2013;30(2):701–6.
26. Dohi O, Yasui K, Gen Y, Takada H, Endo M, Tsuji K, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42(2):411–8.
27. Shi L, Jiang D, Sun G, Wan Y, Zhang S, Zeng Y, et al. miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neurooncol. 2012;110(2):155–62.
28. Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis. 2012;33(5):976–85.
29. Shu M, Zhou Y, Zhu W, Zhang H, Wu S, Chen J, et al. MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. Mol Pharmacol. 2012;81(3):292–8.
30. Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, et al. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 2012;31(11):1398–407.
31. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.
32. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells—old concepts, new insights. Cell Death Differ. 2008;15(6):947–58.
33. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84.
34. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct “side population” of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 2005;4(2):203–5.
35. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.
36. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells—old concepts, new insights. Cell Death Differ. 2008;15(6):947–58.
37. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84.